Skip Navigation

Annals of Oncology 2006 17(Supplement 5):v153-v157; doi:10.1093/annonc/mdj972
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pastorelli, D.
Right arrow Articles by Cillo, U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pastorelli, D.
Right arrow Articles by Cillo, U.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

symposium article

Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature

D. Pastorelli1,*, G. Cartei1, F. Zustovich1, F. Marchese1, G. Artioli1, S. Zovato1, S. Binato1, R. Ceravolo1, S. Cingarlini1, F. Salmaso1, M. Mattiazzi1, C. Sanavio4, F. Farinati3, G. Zanus2 and U. Cillo2

1 O.U.C. Medical Oncology, Busonera Hospital 1st floor, National Oncology Institute of Veneto, IOV - IRCCS, Padua; 2 O.U. Epatobiliary Surgery and Hepatic Transplantation, Padua; 3 Department of Gastroenterologic and Surgery Sciences "P.G. Cevese", Padua; 4 Department of Medicine, General Hospital, Chioggia, Venice, Italy

* Correspondence to: Dr D. Pastorelli, O.U.C. Medical Oncology, 1st floor, Istituto Oncologico Veneto (IOV) - IRCCS, Busonera Hospital, via Gattamelata 64, 35128 Padova, Italy. Tel: +39.049.8215950; Fax: +39.049.8215904; E-mail: dpastorelli{at}ulss16.padova.it

Background: Advanced biliary tract cancers have a poor prognosis. Gemcitabine (G) as a single agent or in combination represents an active treatment option. Systemic chemotherapy in hepatocellular carcinoma represents a palliative treatment. Gemcitabine in combination with Liposomal Doxorubicin (LD) may represent an active treatment option.

Patients and methods: Clinical trials for biliary and hepatic carcinoma have been reviewed.

Results: We obtained RC (1 pt), RP (4 pts), SD (8 pts) and seven pts had PD (RR 25% and SD 40%). Our chemotherapy regimen was Gemcitabine 1000 mg/m2 d 1 and 8, Liposomal Doxorubicin 30 mg d 1, q 28. Patients were 21 (17 M), aged 44 to 78 (median 63 yrs). Only in 8 pts we observed G 3–4 haematological toxicity, thrombocytopenia and neutropenia (7 G3, 1 G4).

Key words: biliary tract cancers, chemotherapy, hepatocellular carcinoma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.